Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Medical technologies specialist Globus Medical (NYSE:GMED) reported impressive results for the fourth quarter of 2024 on ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...